Anthem Biosciences initial public offer (IPO) received a strong response from investors. The IPO was oversubscribed by 63.86 times on Day 3. The offer attracted investors interest across all segments. The Subscriptions details are:
• Retail category: 5.64x,
• Qualified Institutional Buyers: 182.65x, and
• Non-Institutional Investors (NIIs): 42.36x
The IPO was of ₹3,395 crore in value. The subscription was opened on July 14, 2025, and closed on July 16, 2025. ₹540–₹570 was the price band per share, and the minimum investment required was ₹14,040. The allotment date is today, July 17, 2025. And, the listing date for Anthem Biosciences is July 21, 2025.
The public issue has generated significant investor interest, fuelled by Anthem’s role as a major contract research and manufacturing services (CRAMS) provider. Upon confirmation of allotment, equity shares will be credited to eligible investors’ demat accounts on July 18, while refunds for unallocated applications will also be processed on the same day.
How to Check Anthem Biosciences IPO Allotment Status Online
Investors can check their allotment status online through the official sites of NSE, BSE, and Kfin Technologies. Please follow our step-by-step guide:
Check Status on NSE Website
• Visit: https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids
• Select ‘Equity and SME IPO bid details’
• Choose ‘Anthem Biosciences Limited’ from the dropdown menu
• Enter PAN and Application Number
• Click Submit
Check Status on BSE Website
• Visit: https://www.bseindia.com/investors/appli_check.aspx
• For Issue Type, select ‘Equity’
• For Issue Name, choose ‘Anthem Biosciences Limited’
• Enter Application Number or PAN
• Click Search
Check Status on Kfin Technologies
• Visit: https://kosmic.kfintech.com/ipostatus/
• In the IPO dropdown, choose ‘Anthem Biosciences Limited’
• Select Application Number, Demat Account, or PAN
• Enter CAPTCHA
• Click Submit
About the Company
Anthem Biosciences Limited, founded in 2006, operates as a Contract Research, Development & Manufacturing Organization (CRDMO), serving pharmaceutical companies globally. The headquarters of the Anthem Bioscience is in Bangalore.
The company operates in drug discovery, research, and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities.
The clients of Anthem Biosciences include innovation-focused emerging biotech firms and large pharmaceutical companies that operate globally.
Also Read: Mukesh Ambani’s Reliance Shares Slip After Jio IPO Delay, Unlikely To Launch In 2025
Ankur Mishra is a journalist who covers an extensive range of news, from business, stock markets, IPOs to geopolitics, world affairs, international crises, and general news. With over a decade of experience in the business domain, Ankur has been associated with some of the reputed media brands. Through a sharp eye on global marketplaces along with deep insights and analysis of business strategies, Ankur brings simplicity to the complex economic matrix to decode market trends and empower people.
He is committed to entrenched data, facts, research, solutions, and a dedication to value-based journalism. He has covered trade tariff wars, international alliances, corporate policies, government initiatives, regulatory developments, along with micro- and macroeconomic shifts impacting global fiscal dynamics.
